Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 8038 | 2.7 |
09:36 ET | 100 | 2.675 |
09:38 ET | 537 | 2.6503 |
09:41 ET | 100 | 2.675 |
09:45 ET | 100 | 2.68 |
09:48 ET | 1500 | 2.672 |
09:50 ET | 1206 | 2.65 |
09:52 ET | 100 | 2.63 |
09:54 ET | 1050 | 2.635 |
09:56 ET | 300 | 2.63 |
09:57 ET | 100 | 2.63 |
10:01 ET | 516 | 2.63 |
10:03 ET | 1578 | 2.63 |
10:06 ET | 300 | 2.64 |
10:08 ET | 1900 | 2.6301 |
10:12 ET | 2220 | 2.62 |
10:14 ET | 3283 | 2.6105 |
10:15 ET | 522 | 2.6 |
10:17 ET | 2133 | 2.59 |
10:19 ET | 100 | 2.58 |
10:21 ET | 10000 | 2.59 |
10:24 ET | 11479 | 2.61 |
10:26 ET | 3163 | 2.62 |
10:32 ET | 100 | 2.615 |
10:33 ET | 6862 | 2.6001 |
10:37 ET | 581 | 2.61 |
10:39 ET | 1000 | 2.62 |
10:42 ET | 238 | 2.61 |
10:44 ET | 2900 | 2.61 |
10:50 ET | 200 | 2.61 |
10:57 ET | 211 | 2.61 |
11:06 ET | 400 | 2.59 |
11:09 ET | 665 | 2.595 |
11:20 ET | 1816 | 2.63 |
11:33 ET | 2431 | 2.66 |
11:40 ET | 100 | 2.66 |
11:54 ET | 173 | 2.66 |
12:07 ET | 500 | 2.665 |
12:09 ET | 100 | 2.67 |
12:12 ET | 100 | 2.68 |
12:16 ET | 293 | 2.67 |
12:20 ET | 200 | 2.675 |
12:23 ET | 1482 | 2.675 |
12:25 ET | 1006 | 2.6618 |
12:36 ET | 310 | 2.665 |
12:38 ET | 100 | 2.665 |
12:50 ET | 100 | 2.665 |
12:54 ET | 661 | 2.66 |
12:57 ET | 629 | 2.68 |
01:01 ET | 300 | 2.68 |
01:12 ET | 367 | 2.68 |
01:14 ET | 250 | 2.6881 |
01:17 ET | 100 | 2.68 |
01:19 ET | 670 | 2.688 |
01:21 ET | 200 | 2.68 |
01:26 ET | 100 | 2.68 |
01:28 ET | 707 | 2.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 136.8M | -0.7x | --- |
Immunic Inc | 135.1M | -1.0x | --- |
Acumen Pharmaceuticals Inc | 140.6M | -2.2x | --- |
Outlook Therapeutics Inc | 130.6M | -0.7x | --- |
Context Therapeutics Inc | 144.7M | -1.8x | --- |
aTyr Pharma Inc | 130.4M | -1.9x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $136.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.34 |
EPS | $-3.77 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.